Sandbox esophagitis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 39: Line 39:
====Candida====
====Candida====
{{rx|Preferred regimen}}
{{rx|Preferred regimen}}
* [[Fluconazole]] 100–200 mg/day PO/IV for 14-21 days {{and}}
* '''[[Fluconazole]]''' 100–200 mg/day PO/IV for 14-21 days {{and}}
* Maintenance therapy with [[fluconazole]] 100-200 mg/day PO in [[AIDS]] patients
* Maintenance therapy with '''[[fluconazole]]''' 100-200 mg/day PO in AIDS patients
</li>
</li>
{{rx|Alternative regimen}}
{{rx|Alternative regimen}}
* [[Itraconazole]] suspension 100–200 mg PO bid {{or}} [[Voriconazole]] 200 mg PO bid {{or}} [[Amphotericin B]] 0.3–0.7 mg/kg/day IV for 7 days {{or}} [[Caspofungin]] 50 mg/day IV following a 70 mg loading dose {{or}} [[Micafungin]] 150 mg/day IV {{or}} [[Anidulafungin]] 50 mg/day IV following a 100 mg loading dose
* '''[[Itraconazole]]''' suspension 100–200 mg PO bid {{or}} '''[[Voriconazole]]''' 200 mg PO bid {{or}} '''[[Amphotericin B]]''' 0.3–0.7 mg/kg/day IV for 7 days {{or}} '''[[Caspofungin]]''' 50 mg/day IV following a 70 mg loading dose {{or}} '''[[Micafungin]]''' 150 mg/day IV {{or}} '''[[Anidulafungin]]''' 50 mg/day IV following a 100 mg loading dose
</li>
</li>


====Herpes simplex virus====
====Herpes simplex virus====
{{rx|Preferred regimen}}
{{rx|Preferred regimen}}
* [[Acyclovir]] 5 mg/kg IV q8h for 7–14 days {{or}} [[Acyclovir]] 400 mg 5 times daily PO for 14–21 days {{or}} [[Valacyclovir]] 1 g PO tid for 14–21 days ± maintenance therapy
* '''[[Acyclovir]]''' 5 mg/kg IV q8h for 7–14 days {{or}} '''[[Acyclovir]]''' 400 mg 5 times daily PO for 14–21 days {{or}} '''[[Valacyclovir]]''' 1 g PO tid for 14–21 days ± maintenance therapy
</li>
</li>
{{rx|Alternative regimen}}
{{rx|Alternative regimen}}
* [[Famciclovir]] 500 mg bid PO for 14–21 days {{or}} [[Foscarnet]] 90 mg/kg q12h IV for 7–14 days
* '''[[Famciclovir]]''' 500 mg bid PO for 14–21 days {{or}} '''[[Foscarnet]]''' 90 mg/kg q12h IV for 7–14 days
</li>
</li>


====Cytomegalovirus====
====Cytomegalovirus====
{{rx|Preferred regimen}}
{{rx|Preferred regimen}}
* [[Ganciclovir]] 5 mg/kg IV q12h for 14–21 days {{and}}
* '''[[Ganciclovir]]''' 5 mg/kg IV q12h for 14–21 days {{and}}
* Maintenance therapy with [[Ganciclovir]] 5 mg/kg/day IV or 6 mg/kg/day IV 5 days per week in [[AIDS]] patients
* Maintenance therapy with '''[[Ganciclovir]]''' 5 mg/kg/day IV or 6 mg/kg/day IV 5 days per week in AIDS patients
</li>
</li>
{{rx|Alternative regimen}}
{{rx|Alternative regimen}}
* [[Foscarnet]] 90 mg/kg IV q12h for 14–21 days, then [[Foscarnet]] 90–120 mg/kg/day IV for maintenance in [[AIDS]] patients {{or}} [[Valganciclovir]] 900 mg PO bid, then 900 mg PO qd for maintenance in [[AIDS]] patients
* '''[[Foscarnet]]''' 90 mg/kg IV q12h for 14–21 days, then '''[[Foscarnet]]''' 90–120 mg/kg/day IV for maintenance in AIDS patients {{or}} '''[[Valganciclovir]]''' 900 mg PO bid, then 900 mg PO qd for maintenance in AIDS patients
</li>
</li>


====Aphthous ulceration in immunocompromised hosts====
====Aphthous ulceration in immunocompromised hosts====
{{rx|Preferred regimen}}
{{rx|Preferred regimen}}
* [[Prednisone]] 40 mg/day PO for 14 days, tapered over 4–8 weeks
* '''[[Prednisone]]''' 40 mg/day PO for 14 days, tapered over 4–8 weeks
</li>
</li>
{{rx|Alternative regimen}}
{{rx|Alternative regimen}}
* [[Thalidomide]] 200 mg/day PO
* '''[[Thalidomide]]''' 200 mg/day PO
</li>
</li>



Revision as of 15:04, 4 May 2015

Esophagitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Esophagitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sandbox esophagitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox esophagitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox esophagitis medical therapy

CDC on Sandbox esophagitis medical therapy

Sandbox esophagitis medical therapy in the news

Blogs on Sandbox esophagitis medical therapy

Directions to Hospitals Treating Esophagitis

Risk calculators and risk factors for Sandbox esophagitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Treatment of esophagitis should be directed against the specific etiology.

Medical Therapy

Treatment depends on the specific cause. Reflux disease may require medications to reduce acid. Infections will require antibiotics.

  • Medications that block acid production, like heartburn drugs.
  • Antibiotics, antifungals, or antivirals to treat an infection.
  • Pain medications that can be gargled or swallowed.
  • Corticosteroid medication to reduce inflammation.
  • Intravenous (by vein) nutrition to allow the esophagus to heal and to reduce the likelihood of malnourishment or dehydration.
  • Endoscopy to remove any lodged pill fragments.
  • Surgery to remove the damaged part of the esophagus.

While being treated for esophagitis, there are certain steps you can take to help limit discomfort.

  • Avoid spicy foods such as those with pepper, chili powder, curry, and nutmeg.
  • Avoid hard foods such as nuts, crackers, and raw vegetables.
  • Avoid acidic foods and beverages such as tomatoes, oranges, grapefruits and their juices. Instead, try imitation fruit drinks with vitamin C.
  • Add more soft foods such as applesauce, cooked cereals, mashed potatoes, custards, puddings, and high protein shakes to your diet.
  • Take small bites and chew food thoroughly.
  • If swallowing becomes increasingly difficult, try tilting your head upward so the food flows to the back of the throat before swallowing.
  • Drink liquids through a straw to make swallowing easier.
  • Avoid alcohol and tobacco.

Esophagitis of Infectious Etiology

The following pathogens have been reported in the infectious esophagus:

Antimicrobial Regimen – Pathogen-Based Therapy

The selection of pharmacologic agent should be directed against the specific causative pathogen.

Candida

    • Fluconazole 100–200 mg/day PO/IV for 14-21 days AND
    • Maintenance therapy with fluconazole 100-200 mg/day PO in AIDS patients
  • Herpes simplex virus

    • Acyclovir 5 mg/kg IV q8h for 7–14 days OR Acyclovir 400 mg 5 times daily PO for 14–21 days OR Valacyclovir 1 g PO tid for 14–21 days ± maintenance therapy
  • Cytomegalovirus

    • Ganciclovir 5 mg/kg IV q12h for 14–21 days AND
    • Maintenance therapy with Ganciclovir 5 mg/kg/day IV or 6 mg/kg/day IV 5 days per week in AIDS patients
    • Foscarnet 90 mg/kg IV q12h for 14–21 days, then Foscarnet 90–120 mg/kg/day IV for maintenance in AIDS patients OR Valganciclovir 900 mg PO bid, then 900 mg PO qd for maintenance in AIDS patients
  • Aphthous ulceration in immunocompromised hosts

    • Prednisone 40 mg/day PO for 14 days, tapered over 4–8 weeks
  • Eosinophilic Esophagitis

    The optimal treatment of eosinophilic esophagitis remains uncertain. The endpoints of therapy of eosinophilic esophagitis include improvements in clinical symptoms and esophageal eosinophilic inflammation. An eight-week course of therapy with topical corticosteroids (fluticasone 88–440 mcg/day for children or 880–1760 mcg/day for adults or budesonide 1 mg/day for children or 2 mg/day for adults) may be used as the first-line pharmacologic therapy. Patients without symptomatic and histologic improvement after topical steroids may benefit from a longer course or higher doses of topical steroids, systemic steroids with prednisone, dietary elimination, or endoscopic dilation.[1] Evaluation by an allergist for coexisting atopic disorders and food and environmental allergens is advisable. Allergen elimination usually leads to improvement in dysphagia and reduction of eosinophil infiltration. Graduated dilation of esophageal stricture should be performed with caution to minimize the risk of iatrogenic perforation.

    Contraindicated Medications

    Reflux esophagitis is considered an absolute contraindication to the use of the following medications:

    References

    1. Dellon, Evan S.; Gonsalves, Nirmala; Hirano, Ikuo; Furuta, Glenn T.; Liacouras, Chris A.; Katzka, David A.; American College of Gastroenterology (2013-05). "ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)". The American Journal of Gastroenterology. 108 (5): 679–692, quiz 693. doi:10.1038/ajg.2013.71. ISSN 1572-0241. PMID 23567357. Check date values in: |date= (help)